Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | hypothetical protein | 0.0205 | 1 | 1 |
Echinococcus multilocularis | geminin | 0.0205 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3341 | 0.3341 |
Onchocerca volvulus | Protein ultraspiracle homolog | 0.0012 | 0 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 0.3341 | 1 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 0.3341 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 1 | 1 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 0.3341 | 0.3341 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3341 | 0.3341 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3341 | 0.3341 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 0.3341 | 0.3341 |
Onchocerca volvulus | Steroid hormone receptor family member cnr14 homolog | 0.0012 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3341 | 0.3341 |
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Brugia malayi | TAR-binding protein | 0.0076 | 0.3341 | 1 |
Onchocerca volvulus | Bile acid receptor homolog | 0.0012 | 0 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 0.3341 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 0.3341 | 1 |
Brugia malayi | RNA binding protein | 0.0076 | 0.3341 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3341 | 0.3341 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 3.5481 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 10 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Potency (functional) | 18.3564 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 18.3564 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | ||
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.